Tuberculosis and Respiratory Diseases

  • 제62권4호
  • /
  • Pages.270-275
  • /
  • 2007
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

일개 병원의 의료인에서 투베르쿨린 검사와 QuantiFERON-TB Gold 검사를 이용한 잠복결핵의 진단과 치료 전후의 변화

Tuberculin Skin Test and QuantiFERON-TB Gold Assay before and after Treatment for Latent Tuberculosis Infection among Health Care Workers in Local Tertiary Hospital

  • 이승준 (경상대학교 의과대학 내과학교실) ;
  • 김현식 (경상대학교 의과대학 내과학교실) ;
  • 마정은 (경상대학교 의과대학 내과학교실) ;
  • 이상민 (경상대학교 의과대학 내과학교실) ;
  • 함현석 (경상대학교 의과대학 내과학교실) ;
  • 조유지 (경상대학교 의과대학 내과학교실) ;
  • 정이영 (경상대학교 의과대학 내과학교실) ;
  • 김호철 (경상대학교 의과대학 내과학교실) ;
  • 이종덕 (경상대학교 의과대학 내과학교실) ;
  • 김선주 (경상대학교 의과대학 진단검사의학과교실) ;
  • 황영실 (경상대학교 의과대학 내과학교실)
  • Lee, Seung Jun (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Kim, Hyeon Sik (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Ma, Jung Eun (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Lee, Sang Min (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Ham, HyunSeok (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Cho, Yu Ji (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Jeong, Yi Yeong (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Kim, Ho Cheol (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Lee, Jong Deok (Department of Internal Medicine, College of Medicine, Gyeongsang National University) ;
  • Kim, Sun-Joo (Department of Laboratory Medicine, College of Medicine, Gyeongsang National University) ;
  • Hwang, Young Sil (Department of Internal Medicine, College of Medicine, Gyeongsang National University)
  • 투고 : 2007.01.23
  • 심사 : 2007.03.29
  • 발행 : 2007.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

배 경: 결핵의 완전 퇴치를 위해서는 잠복결핵의 진단 및 치료를 통해 활동성 결핵으로 진행되는 것을 예방하는 것이 중요하다. 최근 QuantiFERON-TB Gold 검사가 잠복결핵의 진단을 위한 방법으로 승인되어 사용되고 있다. 본 연구에서는 지역 3차 종합병원에 근무하는 의료인을 대상으로 투베르쿨린 검사와 QuantiFERON-TB Gold 검사를 통해 잠복결핵을 진단하고, 잠복결핵을 치료한 후 투베르쿨린 검사와 QuantiFERON-TB Gold 검사의 변화를 알아보고자 하였다. 방 법: 2006년 경상대학교 병원에 근무중인 의료인 중 48명의 지원자(의사 14명, 간호사 34명, 남:여 =11:37, 평균연령=$29.9{\pm}5.5$세, 평균근무기간=$74.9{\pm}64.3$개월)를 대상으로 하였다. QuantiFERON-TB Gold 검사와 투베르쿨린 검사를 시행하여 의료인에서 잠복 결핵을 진단하고 두 검사의 일치율을 알아보았다. 그리고 QuantiFERON-TB Gold 검사가 양성인 지원자를 대상으로 Isoniazid(INH, 300 mg/day)와 Rifampin( RFP, 600 mg/day)을 3개월간 투약한 후 다시 투베르쿨린 검사와 QuantiFERON-TB Gold 검사를 시행하여 잠복결핵 치료 전후 두 검사의 변화를 확인하고 경결의 양성 기준에 따른 투베르쿨린 검사와 Quanti FERON-TB Gold 검사의 일치율을 알아보았다. 결 과: 48명의 지원자 중 투베르쿨린 검사는 경결 양성 기준을 10 mm 이상으로 하였을 때 19명(39.6%) 에서 양성, QuantiFERON-TB Gold 검사는 8명 (16.7%)에서 양성이었으며 두 검사의 일치율은 77.1%, ${\kappa}$값은 0.468이었고, 투베르쿨린 검사의 경결 양성 기준을 15 mm로 설정하면 두 검사의 일치율은 83.3%, ${\kappa}$값은 0.500이었다. 1명의 활동성 결핵 환자를 제외한 QuantiFERON-TB Gold 검사가 양성인 7명의 지원자에서 잠복결핵 치료 후에도 투베르쿨린 검사와 QuantiFERON-TB Gold 검사는 계속 양성이었다. 이들에게서 시행한 투베르쿨린 검사의 평균 경결은 잠복결핵 치료 전 $19.1{\pm}9.7mm$, 치료 후 $43.6{\pm}25.1mm$이었다. 결 론: 이번 연구의 결론으로는 투베르쿨린 검사와 QuantiFERON-TB Gold 검사로 잠복결핵의 치료 반응을 평가하는 것은 부적절하다고 판단되며 향후 이에 대한 더 많은 연구가 필요할 것으로 사료된다.

The QuantiFERON-TB Gold assay and tuberculin skin test (TST) have been useful test for diagnosing latent tuberculosis infections (LTBI). However, there are few reports on the efficacy of the QuantiFERON-TB Gold assay and TST in evaluating the response after the treatment of LTBI. This study examined the changes in the TST and QuantiFERON-TB Gold assay before and after a treatment for latent tuberculosis in health care workers (HCWs) at a local tertiary hospital. Methods: A cohort of volunteers working as nurses and doctors who underwent a TST and QuantiFERON-TB Gold assay was established. The volunteers positive for the QuantiFERON-TB Gold assay had been treated with 3 months of isoniazid (INH) and rifampin (RFP). After completing treatment, the TST and QuantiFERON-TB Gold assay were repeated. Results: Of the 48 participants (14 doctors, 34 nurses, M: F=11:37, mean $age=29.9{\pm}5.5$ years, mean employment $period=74.9{\pm}64.3$ months), 19 (39.6%) tested positive to the TST (mean induration=$19.1{\pm}9.7mm$) and 8 (16.7%) were QuantiFERON-TB Gold assay. Among them, one had active pulmonary tuberculosis. Seven volunteers were consistently positive to both the TST and QuantiFERON-TB Gold assay after being medicated with INH and RFP for 3 months. Conclusion: TST and QuantiFERON-TB Gold assay are unsuitable for evaluating the treatment response of LTBI because they were consistently positive both before and after the anti-tuberculosis medication.

키워드

참고문헌

  1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement: global burden of tuberculosis:estimated incidence, prevalence, and mortality by country: WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86 https://doi.org/10.1001/jama.282.7.677
  2. Shim TS, Koh WJ, Yim JJ, Lew WJ. Diagnosis and treatment of latent tuberculosis infection in Korea. Tuberc Respir Dis 2004;57:101-17 https://doi.org/10.4046/trd.2004.57.2.101
  3. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001;183:469-77 https://doi.org/10.1086/318081
  4. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of a new specific blood test and the skin test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9 https://doi.org/10.1164/rccm.200402-232OC
  5. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection an interferon-gamma based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64 https://doi.org/10.1164/rccm.200402-179OC
  6. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740-7 https://doi.org/10.1001/jama.286.14.1740
  7. Bellete B, Coberly J, Barnes GL, Ko C, Chaisson RE, Comstock GW, et al. Evaluation of a whole blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis 2002;34:1449-56 https://doi.org/10.1086/340397
  8. Yim JJ, Shim YS, Han SK, Cho BL, Yoon HI, Lee HW, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61 https://doi.org/10.1001/jama.293.22.2756
  9. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, et al. Persistently elevated T cell interferon-$\gamma$ responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 2006;1:7 https://doi.org/10.1186/1745-6673-1-7
  10. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri SP, Mendiratta DK, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole blood, interferon-g assay with tuberculin skin testing. JAMA 2005;293:2746-55 https://doi.org/10.1001/jama.293.22.2746
  11. Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, et al. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003;31:347-53 https://doi.org/10.1016/S0196-6553(02)48240-5
  12. Stuart RL, Olden D, Johnson PD, Forbes A, Bradley PM, Rothel JS, et al. Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis. Int J Tuberc Lung Dis 2000;4:555-61
  13. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, et al. Direct ex vivo analysis of antigen-specific IFN-gamma secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals:associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217-25 https://doi.org/10.4049/jimmunol.167.9.5217
  14. Arend SM, van Meijgaarden KE, de Boer K, de Palou EC, van Soolingen D, Ottenhoff TH, et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002;186:1797-807 https://doi.org/10.1086/345760
  15. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000;55:887-901
  16. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41 https://doi.org/10.1164/ajrccm/145.1.36
  17. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71 https://doi.org/10.1136/adc.78.2.169
  18. Whalen CC, Johnson JL, Okwera A, Hom DL, Hue bner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-8 https://doi.org/10.1056/NEJM199709183371201
  19. Anti-Tuberculosis Drug Resistance in the World (Report No.2, Prevalence and Trends). WHO/CDS/TB/2000.278
  20. Nolan CM, Goldberg SV. Treatment of isoniazid resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis 2002;6:952-8
  21. Medinger A. Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis. Chest 2002;121:1710-2 https://doi.org/10.1378/chest.121.5.1710
  22. Centers for Disease Control and Prevention. Update:fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. JAMA 2002;288:2967 https://doi.org/10.1001/jama.288.23.2967